Lung Cancer

The treatment combination of Rybrevant and chemotherapy significantly improved progression-free survival rates for patients newly diagnosed with metastatic NSCLC with EGFR Exon 20 insertion mutations.

A randomized clinical trial, CHEERS, determined that the combination of stereotactic body radiotherapy (SBRT) and immune checkpoint inhibitors (ICIs) were ineffective as treatment for patients with advanced solid tumors.

I think it was Theodore Geisel (aka Dr Seuss) who said “Don’t cry because it’s over, smile because it happened.”

A blood test protocol proved to be more effective than US Preventative Services Task Force criteria for predicting which patients are at a higher risk of dying from lung cancer.

Patients with both metastatic non-small cell lung cancer and preexisting diabetes mellitus have different outcomes depending on treatment and treatment combinations, particularly with Keytruda and chemotherapy

Patients 65 years and older with NSCLC and undergoing treatment with immunotherapy, chemotherapy and/or targeted therapy were more likely to have worse survival outcomes and declines in activity of daily living.

Patients with stage non-small cell lung cancer tended to have better outcomes when Opdivo was added to their pre-surgical chemotherapy treatment.

The use of Reqorsa and Tecentriq may increase prognosis for patients with extensive-stage small cell lung cancer.

A chemotherapy shortage is resulting in altered treatment plans for many patients with cancer. CURE® spoke with experts about what that means for patients — and what they can do about it.

Treatment with a CAR-M cell therapy plus Keytruda is being assessed in a phase 1 study in patients with HER2-overexpressed tumors.

Studies show that eating a high-fat meal with Alecensa can benefit patients with lung cancer throughout recovery.

A survey of cancer centers found that the majority of large centers are facing cisplatin and carboplatin shortages, and some are changing or delaying treatment because of it.

From Shannen Doherty’s announcement that her breast cancer spread to her brain to a nonprofit being established in memory of the late YouTuber, Technoblade, here’s what’s happening in the oncology space this week.

Tumor treating fields therapy “is a potentially paradigm-shifting new treatment modality” for metastatic non-small cell lung cancer, says Dr. Ticiana Leal.

Adding Keytruda to pre-surgical chemotherapy then giving it again after surgery improved event-free survival and pathologic complete response in patients with early-stage lung cancer.

The agency accepted a New Drug Application for repotrectinib, a TKI for the treatment of patients with locally advanced or metastatic non-small cell lung cancer.

Watch Dr. Jyoti Malhotra and Ken Culver answer questions about the future of the disease during the CURE® Educated Patient® Lung Cancer Summit.

Work is underway in the global phase 3 HARMONi study evaluating the combination of ivonescimab and chemotherapy in the treatment of patients with EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer.

Watch Dr. Jyoti Malhotra, from City of Hope, discuss advancements in advanced non-small cell lung cancer during the CURE® Educated Patient® Lung Cancer Summit.

Watch Dr. Erminia Massarelli, from City of Hope National Medical Center, discuss advancements in early-stage non-small cell disease during the CURE® Educated Patient® Lung Cancer Summit.

Watch Dr. Ravi Salgia, from City of Hope, discuss advancements in small cell lung cancer during the CURE® Educated Patient® Lung Cancer Summit.

Watch Dr. Ed Kim, Dr. Jyoti Malhotra and Terri Conneran answer questions about targeted therapy during the CURE® Educated Patient® Lung Cancer Summit.

Watch Dr. Jyoti Malhotra, from City of Hope Orange County, discuss targeted therapy, during the CURE® Educated Patient® Lung Cancer Summit.

Tagrisso plus chemotherapy improved progression-free survival in patients with EGFR-mutated, locally advanced or metastatic non-small cell lung cancer, according to high-level results from a phase 3 trial.

Watch an expert discuss biomarker testing during the CURE® Educated Patient® Lung Cancer Summit.

Watch Dr. Thomas Waddington and Dr. Percy Lee answer questions about diagnostic and radiation advances during the CURE® Educated Patient® Lung Cancer Summit.

Watch Dr. Percy Lee, from City of Hope, discuss radiation advances during the CURE® Educated Patient® Lung Cancer Summit.

Watch Dr. Thomas Waddington, from City of Hope National Medical Center, discuss the past and future of bronchoscopy during the CURE® Educated Patient® Lung Cancer Summit.

The phase 3 HARMONi trial recently kicked off, studying ivonescimab plus chemotherapy for EGFR-mutant non-small cell lung cancer.

The benefit derived from Tyvyt plus chemotherapy was present regardless of whether previously treated patients with EGFR-mutated, non-squamous non-small cell lung cancer also received Byvasda.